HEREDITARY TRANSTHYRETIN-MEDIATED (HATTR) AMYLOIDOSIS

Clinical trials for HEREDITARY TRANSTHYRETIN-MEDIATED (HATTR) AMYLOIDOSIS explained in plain language.

Never miss a new study

Get alerted when new HEREDITARY TRANSTHYRETIN-MEDIATED (HATTR) AMYLOIDOSIS trials appear

Sign up with your email to follow new studies for HEREDITARY TRANSTHYRETIN-MEDIATED (HATTR) AMYLOIDOSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

Tracking babies born to mothers on rare disease drug

Knowledge-focused Recruiting now

This study aims to collect information about pregnancy outcomes in women who took patisiran-LNP medication for hereditary amyloidosis. Researchers will track birth defects, pregnancy complications, and infant health. The goal is to understand the safety of this medication during …

Matched conditions: HEREDITARY TRANSTHYRETIN-MEDIATED (HATTR) AMYLOIDOSIS

Sponsor: Alnylam Pharmaceuticals • Aim: Knowledge-focused

Last updated Apr 02, 2026 09:27 UTC

HEREDITARY TRANSTHYRETIN-MEDIATED (HATTR) AMYLOIDOSIS

Get alerted when new HEREDITARY TRANSTHYRETIN-MEDIATED (HATTR) AMYLOIDOSIS trials appear

Tracking babies born to mothers on rare disease drug